11208848

Source:http://linkedlifedata.com/resource/pubmed/id/11208848

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008838, umls-concept:C0030705, umls-concept:C0205179, umls-concept:C0205420, umls-concept:C0208407, umls-concept:C0278996, umls-concept:C0920321, umls-concept:C1522449
pubmed:issue	2
pubmed:dateCreated	2001-3-6
pubmed:abstractText	To determine the maximum-tolerated dose of tirapazamine when combined with cisplatin and radiation in patients with T3/4 and/or N2/3 squamous cell carcinoma of the head and neck.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Fluorodeoxyglucose F18, http://linkedlifedata.com/resource/pubmed/chemical/Misonidazole, http://linkedlifedata.com/resource/pubmed/chemical/Radiation-Sensitizing Agents, http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals, http://linkedlifedata.com/resource/pubmed/chemical/Triazines, http://linkedlifedata.com/resource/pubmed/chemical/fluoromisonidazole, http://linkedlifedata.com/resource/pubmed/chemical/tirapazamine
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	0732-183X
pubmed:author	pubmed-author:D'CostaII, pubmed-author:FisherRR, pubmed-author:HaraAA, pubmed-author:HicksRR, pubmed-author:HughesPP, pubmed-author:PetersLL, pubmed-author:RischinDD, pubmed-author:SextonMM, pubmed-author:von RoemelingRR
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	19
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	535-42
pubmed:dateRevised	2008-11-21
pubmed:meshHeading	pubmed-meshheading:11208848-Adult, pubmed-meshheading:11208848-Aged, pubmed-meshheading:11208848-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11208848-Carcinoma, Squamous Cell, pubmed-meshheading:11208848-Cell Hypoxia, pubmed-meshheading:11208848-Cisplatin, pubmed-meshheading:11208848-Combined Modality Therapy, pubmed-meshheading:11208848-Dose Fractionation, pubmed-meshheading:11208848-Drug Administration Schedule, pubmed-meshheading:11208848-Fluorodeoxyglucose F18, pubmed-meshheading:11208848-Head and Neck Neoplasms, pubmed-meshheading:11208848-Humans, pubmed-meshheading:11208848-Middle Aged, pubmed-meshheading:11208848-Misonidazole, pubmed-meshheading:11208848-Radiation-Sensitizing Agents, pubmed-meshheading:11208848-Radiopharmaceuticals, pubmed-meshheading:11208848-Survival Analysis, pubmed-meshheading:11208848-Tomography, Emission-Computed, pubmed-meshheading:11208848-Triazines
pubmed:year	2001
pubmed:articleTitle	Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
pubmed:affiliation	Division of Hematology and Medical Oncology, and Statistical Centre, Peter MacCallum Cancer Institute, Melbourne, Australia. drischin@petermarc.unimelb.edu.au
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I